Ketamine Bioavailability by Route: A Patient Comparison

Patients comparing low-dose ketamine options often run into the same confusing fact: a 100 mg sublingual troche and a 100 mg intravenous infusion are not remotely the same dose. The reason is bioavailability — the percentage of the dose that actually reaches the bloodstream. This guide compares the main routes used in real-world low-dose protocols and explains why route, not just milligrams, drives the experience.

What Bioavailability Means in Practice

Bioavailability is the fraction of a dose that reaches systemic circulation as active drug. Intravenous administration delivers the drug directly into the bloodstream and is set at 100 percent by definition. Every other route involves a barrier — the gut wall, the liver, the oral or nasal mucosa, or muscle tissue. Each barrier reduces, delays, or both, how much active ketamine ends up in the bloodstream.

For ketamine the biggest barrier is first-pass liver metabolism, which converts a large share of swallowed ketamine into norketamine before it can act as the parent drug. That is why pure oral (swallowed) ketamine has the lowest bioavailability of the main routes, and why prescribers reach for sublingual or other partly-bypassing routes when they want a more predictable response at a manageable milligram total.

How the Main Routes Compare

Reported ranges differ across published sources because individual physiology, technique, and formulation all play a role. The figures below are typical published ranges, not exact constants. Your own bioavailability sits somewhere inside a band, not on a single number.

Why Sublingual Sits in the Middle

Sublingual ketamine — usually as a compounded lozenge or troche — partly bypasses first-pass metabolism by absorbing through the oral mucosa. Reported bioavailability ranges commonly land in the 20-30 percent band, depending on technique. Patients who chew, swallow the saliva early, or take the troche with food generally end up closer to the lower end of that band. Patients who let the lozenge dissolve slowly and quietly under the tongue without swallowing for 7-15 minutes tend toward the higher end.

This is why two patients on identical prescriptions can describe quite different experiences. The label number is the milligrams of ketamine in the troche, not the milligrams that reach the bloodstream.

Why Route Shapes the Experience, Not Just the Dose

Bioavailability is only part of why routes feel different. Onset speed, peak blood level, and time-to-clearance also vary. An IV infusion produces a high, controlled peak over a short window. A sublingual troche produces a smoother, lower peak over a longer window. Two protocols can deliver the same total exposure on paper but feel very different in the chair or on the couch at home.

For low-dose maintenance care, the sublingual route is popular precisely because of that smoother profile: predictable enough to schedule, mild enough for at-home use under telehealth oversight, and bypassing enough of first-pass metabolism to keep doses in a manageable range.

What This Means When You Compare Doses Across Routes

1. Do not assume a sublingual milligram equals an IV or IM milligram — they are not interchangeable currencies.
2. Technique matters: how a sublingual dose is held in the mouth can shift bioavailability by several percentage points.
3. Food, fluids, and gastric pH change oral absorption — most prescribers ask patients to avoid eating shortly before dosing.
4. Switching routes is a prescription change, not a math problem — talk to a licensed clinician before any switch.
5. Track effect intensity by session along with dose and timing; this is more useful than chasing a target milligram number.

Safety, Contraindications, and Reasonable Expectations

Regardless of route, ketamine therapy is not appropriate for everyone. Uncontrolled hypertension, recent cardiovascular events, severe liver disease, untreated psychotic disorders, active substance use disorder involving sedatives, pregnancy, and breastfeeding are common reasons to avoid or pause treatment. Combinations with benzodiazepines, opioids, Z-drugs, alcohol, and other sedatives raise sedation and respiratory risk and should always be reviewed by a clinician before use.

Bioavailability charts are useful for understanding why protocols look the way they do — they are not dosing instructions. The dose, route, and frequency that is right for you belongs in a structured conversation with a licensed clinician, not in a percentage table.